你好!欢迎访问 登录|立即注册

0576-88813233

|
浙江省台州市椒江开发大道东段288号万达广场2号楼
0576-88813233
0576-88670057
sales@crene.cn
合作客户/Partner
当前位置:科瑞产品

贝前列素钠Beraprost sodium

贝前列素钠Beraprost sodium 88475-69-8
规格 价格 库存 数量
在线咨询 大包装询价 加入购物车
如您需要更多数量的报价,请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您,谢谢!
产品信息
产品名称:贝前列素钠Beraprost sodium 纯度:98%min
CAS NO:88475-69-8 溶解度:Soluble in DMSO
分子式:C24H29NaO5 包装:可按客户要求包装。
分子量:420.47 贮存:Store at -20℃ 3 years
质量控制
COA
备注说明

Beraprost is an analog of prostacyclin in which the unstable enol-ether has been replaced by a benzofuran ether function. This modification increases the plasma half-life from 30 seconds to several hours, and permits the compound to be taken orally. Doses of 20-100 µg in humans, given 1 to 3 times per day, have been demonstrated to improve clinical end points in diseases responsive to prostacyclin. Oral beraprost therapy improved the survival and pulmonary hemodynamics of patients with primary pulmonary hypertension.1 Beraprost inhibits platelet aggregation in healthy subjects and in diabetic patients at similar doses.2,3

参考文献

1. Nagaya, N., Uematsu, M., Okano, Y., et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. Journal of the American College of Cardiology 34, 1188-1192 (1999).

2. Nony, P., Ffrench, P., Girard, P., et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: A study in healthy male subjects. Canadian Journal of Physiology and Pharmacology 74, 887-893 (1996).

3. Kato, H., Takashima, T., Kishikawa, H., et al. Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus. International Journal of Clinical Pharmacology Research 16, 99-102 (1996).

版权所有 Copyright(C) 2018-2021 台州市科瑞生物技术有限公司

公司所列产品中涉及到专利,只供研发使用,不做销售;管制产品将严格遵守中国法律和购买客户国法律的规定销售,所有产品都不适用于人用 如被销售到构成专利侵权的国家,则相应的一切风险将由买方承担。